Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Bladder Cancer treatment details. Biologic therapy. Chemotherapy. Georges Pompidou Hospital, University Paris Descartes, Paris, France



Survival: 14.1 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
Chemotherapy
   
Drugs:
Country: France
   
City/State/Province: Paris
   
Hospital: Georges Pompidou Hospital, University Paris Descartes
   
Journal: Link
   
Date: 11/2014

Description:
Patients:
This phase 2 study involved patients with advanced or metastatic, HER2-overexpressing urothelial carcinoma who were separated into two treatment groups. Group A consisted of 29 patients with a median age of 66 years and 93% were male. Group B had 32 patients with a median age of 64 years and 84% were male.

Treatment:
Patients in group A received chemotherapy with gemcitabine and either cisplatin or carboplatin.
Patients in group B received biologic therapy with trastuzumab in addition to chemotherapy with gemcitabine and either cisplatin or carboplatin

Toxicities:
The most severe toxicities in group A were of grade 4 and included grade 3-4 neutropenia, anemia, and diarrhea. Grade 1-2 nausea and constipation were also reported.

There was one treatment-related death due to febrile neutropenia in group B. Grade 3-4 anemia, nausea/vomiting, and diarrhea were also reported.

Results:
The median overall survival rates for groups A and B were 15.7 and 14.1 months, respectively.

Support:
This study was supported by Roche SAS.

Correspondence: Dr. Stephane Oudard; email: stephane.oudard@egp.aphp.fr

E-mail to a Friend Email Physician More Information